Nanopore sequencing shows potential for personalised oncogenomics
There has been an error loading the video, please reload the page.
Since 2012, our centre has run a successful personalised oncogenomics (POG) trial for patients with advanced cancers using short-read whole-genome and transcriptome analysis of tumours to inform clinical decisions. But nanopore sequencing can improve structural variant resolution, while providing phasing and methylation information. To assess these capabilities, we have sequenced and analysed seven tumours from the POG trial. We will showcase these results, and highlight opportunities for bioinformatics tool development. We have recently sequenced 182 additional cases, with a focus on those with suspected epigenomic dysregulation and complex structural variants. We will show preliminary results from these studies.
To learn more about other applications of nanopore sequencing in cancer research, click here.